Anti-B antibody (Anti-B)

Anti-B antibodies are naturally occurring isohemagglutinins found in the plasma of individuals with blood group A or O (StatPearls, NBK482281). These antibodies, primarily of the IgM and IgG classes, are directed against the B carbohydrate antigen expressed on the surface of red blood cells and various other tissues, including the vascular endothelium (NIH, NBK2267). In clinical medicine, anti-B antibodies are significant targets for intervention during ABO-incompatible organ transplantations and in cases of hemolytic disease of the newborn. If not properly managed, these antibodies can trigger hyperacute rejection or acute hemolytic transfusion reactions through the activation of the classical complement pathway and subsequent cell lysis (PubMed, 25612484). Therapeutic management typically involves desensitization protocols that utilize plasmapheresis or immunoadsorption for physical removal, alongside immunosuppressive agents like rituximab to suppress the production of new antibodies (PubMed, 30146051). Monitoring anti-B titers is essential for assessing the risk of immune-mediated damage and ensuring the success of incompatible grafts.

Other names

Anti-B isohemagglutininBlood group B antibodyABO antibody anti-BIsohemagglutinin anti-B

Therapeutic strategies target anti-B antibodies through the depletion of antibody-producing B-cells and plasma cells, physical removal from the circulation via apheresis, or the inhibition of the complement cascade to prevent antibody-mediated cytotoxicity and tissue damage.